Triple-negative breast cancer: clinical features and patterns of recurrence, Clin Cancer Res, vol.13, pp.4429-4434, 2007. ,
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J Clin Oncol, vol.26, pp.1275-1281, 2008. ,
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98, J Clin Oncol, vol.31, pp.860-867, 2013. ,
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial, Ann Oncol, vol.25, pp.1544-1550, 2014. ,
Prognostic value of tumorinfiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199, J Clin Oncol, vol.32, pp.2959-2966, 2014. ,
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J Clin Oncol, vol.28, pp.105-113, 2010. ,
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer-a substudy of the neoadjuvant GeparQuinto trial, PLoS One, vol.8, 2013. ,
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, vol.121, pp.2750-2767, 2011. ,
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes, Clin Cancer Res, vol.19, pp.5533-5540, 2013. ,
Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection, PLoS One, vol.11, 2016. ,
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment ,
, Ann Oncol, vol.22, pp.515-523, 2011.
The role of inflammation in inflammatory breast cancer, Adv Exp Med Biol, vol.816, pp.53-73, 2014. ,
Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers, Breast Cancer Res, vol.15, 2013. ,
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets, Clin Cancer Res, vol.19, pp.4685-4696, 2013. ,
,
Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study, Cancer, vol.117, pp.1819-1826, 2011. ,
TNBCtype: a subtyping tool for triple-negative breast cancer, Cancer Inform, vol.11, pp.147-156, 2012. ,
Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients, BMC Cancer, vol.16, p.26908167, 2016. ,
Mesenchymal stromal cells can regulate the immune response in the tumor microenvironment, Vaccines, vol.4, p.41, 2016. ,
Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas, Cancer Res, vol.77, pp.3982-3989, 2017. ,
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics, Cancer Res, vol.69, pp.4116-4124, 2009. ,
Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy, Breast Cancer Res Treat, vol.148, p.25395319, 2014. ,
Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer, Clin Cancer Res, vol.16, pp.45-55, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-01431949
Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways, Mol Cancer, vol.16, p.28270211, 2017. ,